Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL... see more

Recent & Breaking News (NDAQ:EQ)

Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

GlobeNewswire December 12, 2019

Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis

GlobeNewswire December 9, 2019

Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire November 26, 2019

Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health

GlobeNewswire November 15, 2019

Equillium Announces Leadership Updates

GlobeNewswire November 12, 2019

Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights

GlobeNewswire November 12, 2019

Equillium to Present at Investor Conferences in November 2019

GlobeNewswire November 7, 2019

Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019

GlobeNewswire November 6, 2019

Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board

GlobeNewswire October 31, 2019

Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update

GlobeNewswire October 1, 2019

Equillium to Host Business Update Call on October 1, 2019

GlobeNewswire September 17, 2019

Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference

GlobeNewswire August 27, 2019

Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights

GlobeNewswire August 12, 2019

Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma

GlobeNewswire July 10, 2019

Equillium to Present at Jefferies 2019 Healthcare Conference

GlobeNewswire May 23, 2019

Equillium Reports First Quarter 2019 Financial Results and Recent Highlights

GlobeNewswire May 13, 2019

Equillium Expands Scientific and Clinical Advisory Team

GlobeNewswire May 6, 2019

Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day

GlobeNewswire April 16, 2019